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Abstract
The protozoan parasite Trypanosoma cruzi, which causes human Chagas’ disease, exerts a variety of effects on host
extracellular matrix (ECM) including proteolytic degradation of collagens and dampening of ECM gene expression. Exposure
of primary human dermal fibroblasts to live infective T. cruzi trypomastigotes or their shed/secreted products results in a
rapid down-regulation of the fibrogenic genes collagenIa1, fibronectin and connective tissue growth factor (CTGF/CCN2).
Here we demonstrate the ability of a secreted/released T. cruzi factor to antagonize ctgf/ccn2 expression in dermal
fibroblasts in response to TGF-ß, lysophosphatidic acid or serum, where agonist-induced phosphorylation of the mitogen-
activated protein (MAP) kinases Erk1/2, p38 and JNK was also inhibited. Global analysis of gene expression in dermal
fibroblasts identified a discrete subset of TGF-ß-inducible genes involved in cell proliferation, wound repair, and immune
regulation that are inhibited by T. cruzi secreted/released factors, where the genes exhibiting the highest sensitivity to T.
cruzi are known to be regulated by MAP kinase-activated transcription factors. Consistent with this observation, the Ets-
family transcription factor binding site in the proximal promoter region of the ctgf/ccn2 gene (291 bp to 284 bp) was
shown to be required for T. cruzi-mediated down-regulation of ctgf/ccn2 reporter expression. The cumulative data suggest a
model in which T. cruzi-derived molecules secreted/released early in the infective process dampen MAP kinase signaling and
the activation of transcription factors that regulate expression of fibroblast genes involved in wound repair and tissue
remodelling, including ctgf/ccn2. These findings have broader implications for local modulation of ECM synthesis/
remodelling by T. cruzi during the early establishment of infection in the mammalian host and highlight the potential for
pathogen-derived molecules to be exploited as tools to modulate the fibrogenic response.
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Introduction
The kinetoplastid protozoan parasite Trypanosoma cruzi causes
Chagas’ disease in humans, a chronic and debilitating condition
affecting several million individuals in Latin America. T. cruzi is
transmitted by an insect vector which gains access to the host via
breaches in the skin or through mucosal membranes, mainly
conjunctival or gastric mucosa [1,2]. As an obligate intracellular
parasite that disseminates from initial infection sites to tissues such
as heart and smooth muscle, T. cruzi undergoes multiple rounds of
invasion, growth and egress from infected cells during the acute
stage of infection. Very little is currently known regarding the early
interactions between T. cruzi and its host that facilitate establish-
ment of infection in vivo. Cellular models of T. cruzi infection have
been very useful for defining the molecular and cellular events that
regulate the early parasite-host cell interactions and host cell
invasion. During its early interaction with mammalian host cells,
trypomastigotes, the invasive forms of T. cruzi, trigger rapid
changes in a number of cellular signaling pathways to facilitate the
process of parasite entry into non-professional phagocytic cells
(reviewed in [3,4]). While these early signaling events have been
relatively well-studied in the context of T. cruzi invasion, little is
known regarding the impact of these parasite-induced signaling
cascades downstream of the invasion process. Transcriptional
profiling of T. cruzi-infected fibroblasts revealed that the earliest
detectable changes triggered by infective T. cruzi trypomastigotes
involve down-regulation of a small subset of genes including
members of the CCN family (cyr61 and ctgf/ccn2) [5], which play
important roles in angiogenesis and extracellular matrix (ECM)
homeostasis [6]. T. cruzi-dependent dampening of ctgf/ccn2 expres-
sion occurs at both the mRNA and protein levels and is mediated
by a secreted/released parasite factor that is capable of
antagonizing TGF-ß-mediated induction of ctgf/ccn2 [7].
Connective tissue growth factor (CTGF/CCN2) is a 38 kDa
secreted cysteine-rich heparin-binding glycoprotein [8] that
promotes cell proliferation and co-operates with TGF-ß to
promote myofibroblast differentiation and enhanced extracellular
matrix (ECM) synthesis (reviewed in [9]). Dysregulation of
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and this cytokine is over-expressed in a variety of tumors where
CTGF/CCN2 levels correlate with disease progression [9]. As
such there has been significant interest in CTGF/CCN2 as a
therapeutic target for a number of disease states [10,11,12,13].
Our finding that the human pathogen, Trypanosoma cruzi, releases a
factor that inhibits TGF-ß-mediated expression of CTGF/CCN2
prompted further investigation into the mechanistic basis for this
observation. CTGF/CCN2 expression is induced by diverse
extracellular stimuli, including growth factors, cytokines and
mechanical stress [9,14,15,16,17]. TGF-ß-stimulated expression
of CTGF/CCN2 requires the activation of SMAD proteins and
MAP kinases downstream of the TGF-ß receptor [9,15]. Erk1/2
and p38 are generally associated with positive regulation of
CTGF/CCN2 expression in different cell types [15,18,19,20],
whereas the role of JNK is more variable [15,18,20]. The
expression of CTGF/CCN2 is also controlled via the activities of
the ETS family of transcription factors. A functional Ets-binding
site identified in the proximal ctgf/ccn2 promoter, spanning the
region 291 to 284 bp upstream of the transcriptional start site, is
bound by Ets-1 to promote TGF-ß-dependent induction of ctgf/
ccn2 [21], while binding of the same site by Fli-1 negatively
regulates ctgf/ccn2 expression in human fibroblasts [22]. The
activity of many members of the ETS family is controlled through
MAP kinase signaling, where the DNA-binding and trans-
activation activities of ETS transcription factors are regulated by
phosphorylation [23,24].
In the present study, we demonstrate that T. cruzi-dependent
abrogation of ctgf/ccn2 expression in human dermal fibroblasts is
associated with inhibition of both basal and agonist-induced
activation of MAP kinase signaling and requires the functional Ets-
binding site in the proximal promoter of the ctgf/ccn2 gene.
Expanding our analysis of the impact of T. cruzi released factors on
TGF-ß-induced fibroblast gene expression we describe a discrete
subset of agonist-inducible fibroblast genes that are sensitive to T.
cruzi secreted/released factors. We report that the group of TGF-
ß-inducible genes that exhibit the highest sensitivity to a T. cruzi
secreted/released fraction are MAP kinase-regulated genes that
function in wound repair, extracellular matrix remodelling and
host response pathways. Collectively, these findings provide novel
insights into early T. cruzi-host cell interactions. We demonstrate
the ability of secreted/released parasite molecules to hinder
agonist-induced host cell signaling pathways and gene expression.
If similar events occur early in the T. cruzi infection process in vivo,
it would be predicted that local inhibition of ECM synthesis would
facilitate dissemination from initial sites of infection.
Results
A secreted/released trypanosome factor inhibits agonist-
induced expression of CTGF/CCN2 in human dermal
fibroblasts
Connective tissue growth factor (CTGF/CCN2) expression is
rapidly repressed in human dermal fibroblasts infected with the
protozoan parasite, Trypanosoma cruzi, where the CTGF/CCN2-
repressive activity was shown to be associated with a secreted/
released trypanosome factor that is present in parasite-conditioned
medium (PCM) [5] [7]. While the repressive factor released from
live infective T. cruzi trypomastigotes into the medium (parasite-
conditioned medium; PCM) [7] has not been identified, it is
associated with a trypsin-sensitive, heat-labile, high molecular
weight protein fraction of T. cruzi PCM enriched in GPI-anchored
surface proteins (A. Mott and B. Burleigh, unpublished data). Here
we show that treatment of human dermal fibroblasts (HFF) with T.
cruzi PCM blocks induction of ctgf/ccn2 expression triggered by
different agonists TGF-ß (Figure 1A, B), serum (Figure 1C) or
lysophosphatidic acid (LPA) (Figure 1D). Thus, the ability of T.
cruzi PCM to inhibit ctgf/ccn2 expression in response to distinct
exogenous agonists suggests that signaling molecules primarily
associated with TGF-ß receptor signaling such as the SMADs, are
unlikely to be the downstream target of T. cruzi PCM leading to
the repression of ctgf/ccn2.
T. cruzi PCM inhibits agonist-induced MAP kinase
activation
Given the well-established role of MAP kinase signaling in the
regulation of ctgf/ccn2 expression in a variety of cell types [15,18,
19,20,25,26], Erk1/2, JNK and p38, were targeted in HFF with
selective inhibitors to determine the impact on TGF-ß-inducible
expression of ctgf/ccn2. Added individually, inhibitors of Erk1/2,
JNK and p38 partially inhibited TGF-ß-dependent up-regulation
of ctgf/ccn2 whereas in combination, the inhibitors were much
more effective (Figure 2A) suggesting that different arms of the
MAP kinase signaling pathway are involved in regulation of ctgf/
ccn2 expression in HFF. As predicted from this result, stimulation
of HFF with TGF-ß (5 ng/ml) or LPA (10 mM) promotes
increased phosphorylation of Erk1/2, JNK and p38, which
migrate on western blots at the expected molecular weights of
40 kDa, 45 kDa and 39 kDa respectively, where T. cruzi PCM
abrogates both TGF-ß and LPA-induced phosphorylation of these
kinases (Figure 2B). Combined, the data suggest that T. cruzi PCM
exerts an inhibitory effect on ctgf/ccn2 expression by dampening
MAP kinase signaling pathways.
An Ets binding site in the proximal ctgf/ccn2 promoter is
involved in T. cruzi-mediated repression of gene
expression
The ctgf/ccn2 promoter/enhancer region contains several pro-
tein-binding sites that have been implicated in regulation of gene
expression [21,22,27,28,29,30]. Focusing on the proximal promoter
region of ctgf/ccn2 (Figure 3A), we tested the impact of T. cruzi PCM
treatment on basal and TGF-ß stimulated reporter activity using a
series of ctgf/ccn2 promoter/SEAP reporter plasmids [21,27]
transfected into human dermal fibroblasts. As previously described,
reporters containing functional Smad3 and Ets-binding sites: ie.
spanning regions -805 to +17 bp (Figure 3B; 2805)o r2244 to
+17 bp (Figure 3B ; 2244)o ft h ectgf/ccn2 promoter were activated
byTGF-ßwhereasaseverelytruncatedpromoter/reporterspanning
286 to +17 bp of the ctgf/ccn2 promoter (Figure 3B; 286) failed to
activate following TGF-ß stimulation. T. cruzi PCM treatment
resulted in a significant decrease in basal activity of the 2805 and
2244 reporter constructs and blocked TGF-ß mediated activation
of these reporters (Figure 3B). In contrast, basal expression of the
reporter from the truncated construct (Figure 3B; 286) did not
change in response to T. cruzi PCM. These data suggest that the Ets
site present at 291 to 284 bp upstream of the transcriptional start
site inthepromoterisrequired to mediatetherepressiveeffects ofT.
cruzi PCM on ctgf/ccn2 gene expression. In order to confirm this
critical role for the Ets consensus site in PCM-mediated repression
of ctgf/ccn2 expression, we examined the effect of T. cruzi PCM on
the full-length reporter containing a mutated Ets site (Figure 3B;
2805 ETS). As previously reported, a functional Ets binding site is
required for TGF-ß-stimulated ctgf/ccn2 gene expression, and there-
fore this reporter is refractory to TGF-ß treatment (Figure 3B).
Critically, a comparison between the response of the 2805 and the
mutant 2805 ETS to PCM demonstrates the inability of PCM to
repress activity in the absence of a functional Ets binding site
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Ets binding site in the ctgf/ccn2 promoter is essential for TGF-ß
dependent gene expression, and imparts sensitivity to T. cruzi-
mediated inhibition of ctgf/ccn2 gene expression.
T. cruzi PCM inhibits the expression of a subset of MAP
kinase-regulated fibroblast genes involved in wound
repair
Results presented above demonstrate that the factor(s) that are
secreted or shed by T. cruzi trypomastigotes antagonize MAP
kinase signaling in HFF downstream of TGF-ß and LPA. To
determine the global impact of T. cruzi PCM on both basal and
TGF-ß stimulated gene expression in human dermal fibroblasts,
transcriptomic analyses were conducted following exposure of
HFF to TGF-ß (5 ng/ml) in the presence or absence of T. cruzi
PCM for 3 hours. cDNA prepared from treated and control cells
were hybridized to human Affymetrix arrays containing ,47,000
probesets (HG_U_133, 2.0). Raw expression data from triplicate
experiments was imported into, and processed using, Rosetta
Resolver 7.0 as outlined in the Experimental Procedures. Genes
with expression levels that differed by 2-fold or greater (p,0.01)
between the different experimental groups were considered for
further analysis.
Examining first the impact of the secreted/released T. cruzi
fraction on fibroblast gene expression, we find 89 unique genes (in
121 probe-sets) consistently down-regulated in PCM-treated cells
and 82 genes (in 107 probe-sets) up-regulated greater than 2-fold
(Table S1). Many of the repressed genes are ‘immediate early’
genes that regulate transcription (egr-1, jun, myc, fos, KLF2, KLF6)
and are involved in cell proliferation [31,32,33,34,35] and inflam-
mation [36,37,38]. As predicted from our studies with ctgf/ccn2, T.
cruzi PCM treatment also results in the down-regulation of genes
that are involved in extracellular matrix synthesis and tissue
remodeling including hyaluronan synthase 2 (HAS2), tenascin C
(TNC) and the CCN family members ctgf/ccn2 and cyr61 [17].
T. cruzi PCM inhibited the expression of approximately 30% of
the with TGF-ß-inducible genes in HFF (Table S2). The 59 genes
appearing in Table 1 represent the annotated, non-redundant
TGF-ß inducible genes for which expression was inhibited by 1.7-
fold or greater by T. cruzi PCM. Among the most highly PCM-
sensitive, TGF-ß inducible genes are those with known involve-
ment in extracellular matrix remodeling, wound healing and
angiogenesis including heparin-binding EGF-like growth factor
(HBEGF), angiopoietin-like 4 (ANGPTL4), endothelin-1 (EDN1),
tropomyosin 1 (TPM1), chondroitin 4-sulfotransferase (CHST11),
early growth response 1 (egr-1), connective tissue growth factor
Figure 1. T. cruzi PCM inhibits agonist-induced ctgf/ccn2 expression. HFF were incubated with medium or T. cruzi PCM, alone or in
combination with 5 ng/ml TGF-ß, 2 hours prior to mRNA harvest for quantitative real-time PCR analysis (A) or 24 hours prior to analysis of CTGF/
CCN2 protein levels by western blot (B). ctgf/ccn2 mRNA levels were analyzed by quantitative real-time PCR following stimulation of HFF with serum
(2% v/v) (C) or 10 mM LPA (D) for 2 hours in the presence or absence of T. cruzi PCM. Data is represented as the mean 6 S.E. from 5 independent
experiments carried out in duplicate. Statistical significance was assessed using the Student’s t-test, (** p,0.01).
doi:10.1371/journal.pone.0023482.g001
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addition, interleukin 6 (IL-6), chemokine (C-C motif) ligand 2
(CCL2) and prostaglandin-endoperoxide synthase 2 (PTGS2),
which have been grouped with PCM-sensitive genes involved in
inflammation and immune regulation (Table 1), also play an
important role in wound repair [39,40,41,42]. In support of the
proposed role for MAP kinase-inhibition in mediating the effects of
T. cruzi PCM on fibroblast gene expression, the TGF-ß-inducible
genes with the highest sensitivity to T. cruzi PCM-mediated
repression in the microarray analysis (ie. those for which a 4-fold
or greater inhibition of TGF-ß-mediated induction of target gene
expression was observed: EGR1 (17-fold), HBEGF (13-fold), PTGS2
(8.2-fold), LIF (7-fold), EDN1 (5.7-fold), IL6 (5.5-fold), CYR61 (4-
fold)) are known to be regulated by MAP kinase activated
transcription factors such as ETS-family transcription factors,
AP-1 and NF-kB in a variety of cell types [43,44,45,46,47,48,49].
Quantitative RT-PCR carried out to confirm the pattern of PCM
sensitivity for several TGF-ß inducible genes (Figure 4) reveals
consistency with the microarray data where T. cruzi PCM was
shown to inhibit TGF-ß dependent induction of HBEGF, CTGF/
CCN2, PTSG2 and Cyr61. In contrast, TGF-ß stimulated expres-
sion of SERPINE2, CDKN2B, SMAD7 and TSPAN2 were refractory
to PCM treatment (Figure 4). These data highlight both the
broader effect of T. cruzi-derived factors on fibroblast gene expres-
sion and reveal selectivity of the response as only a subset of TGF-
ß-inducible genes were affected when cells were co-stimulated with
T. cruzi PCM.
Biological network analysis conducted using the Ingenuity
Pathway Analysis
TM software program reveals a dense set of
relationships between the subset of T. cruzi PCM sensitive
Figure 2. T. cruzi PCM abrogates MAP kinase activation and decreased MAP kinase signaling results in inhibition of ctgf/ccn2
expression. (A) HFF were stimulated with 5 ng/ml TGF-ß1 in the presence of medium, T. cruzi PCM or with 10 mM SP600125, 20 mM SB203580 or
50 mM PD98059 as indicated for 2 hours prior to mRNA harvest for quantitative real-time PCR analysis. MAP kinase inhibitor treatments were carried
out following a 30-minute pre-incubation step. Data is represented as the mean 6 s.e. from triplicate experiments (n=4). Statistical significance was
assessed using the Student’s t-test (** p,0.01, * p,0.05). (B) Western blot of phospho-Erk, phospho-JNK and phospho-p38 normalized to total Erk,
JNK and p38 respectively in lysates from HFF stimulated with 5 ng/ml TGF-ß1 or 10 mM LPA for 5 or 15 minutes in serum-free media or parasite-
conditioned medium. Results for densitometric analysis are shown as numerical values below each panel and represented as phosphorylation relative
to mock-treated controls (arbitrarily set to a value of 1.0).
doi:10.1371/journal.pone.0023482.g002
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functions associated with this network include ‘cellular growth’,
‘cancer’ and ‘connective tissue development and function’. A
comparative analysis of the top canonical pathways represented in
the T. cruzi PCM-sensitive and PCM-insensitive TGF-ß inducible
gene datasets are shown in Table S3. The top canonical pathways
associated with the PCM-sensitive genes reveal 5 pathways with
significant p-values (p,0.05) including ‘hepatic fibrosis/hepatic
stellate cell activation’ (CTGF, FN1, TGFb2, EDN1, CCL2, IL-6)a s
the most significant pathway affected by the secreted/shed T. cruzi
fraction. In contrast, when the PCM-insensitive group of TGF-ß-
inducible genes was considered, the top functions involved ‘axonal
guidance’ and ‘clathrin-mediated endocytosis signaling’ (Table S4)
[43,44,45,46,47,48,49]. Collectively, the global expression data are
supportive of a model in which infective T. cruzi trypomastigotes
secrete or release factors that within minutes dampen MAP kinase
signaling in human dermal fibroblasts. We propose that this
dampening of host cell MAP kinase activity negatively impacts the
activities of downstream transcription factors such as the ETS
family of transcription factors known to be involved in the
regulation of a number of genes involved in ECM synthesis and
wound repair [50,51] including ctgf/ccn2 gene expression [21,
22,51].
Discussion
This study demonstrates that mammalian-infective forms of
Trypanosoma cruzi release a factor (or factors) that significantly
impacts host cell signaling cascades, thereby altering the
expression of a subset of genes involved in cell proliferation,
wound repair and inflammation. Focusing on the pro-fibrogenic
cytokine, CTGF/CCN2, a multifunctional secreted protein with a
central role in wound repair and fibrosis [9], we demonstrate that
a shed/secreted T. cruzi factor inhibits both basal and agonist-
induced up-regulation of ctgf/ccn2 gene expression. In line with
previous reports demonstrating a critical role for MAP kinases in
regulating ctgf/ccn2 gene expression in response to pro-fibrogenic
agonists [15,17,18,19,20], our data demonstrate a role for Erk1/2,
JNK and p38 in TGF-ß-mediated ctgf/ccn2 expression in low
passage primary HFF. Exposure of HFF to the shed/secreted T.
cruzi fraction inhibits basal and agonist-dependent phosphorylation
of Erk1/2, JNK and p38 and the induction of ctgf/ccn2 expression,
a downstream target of MAP kinase activation [15]. Analysis of the
global transcriptional response to T. cruzi PCM in HFF revealed
significant repression of a subset of TGF-ß-inducible genes involved
in cell proliferation, wound healing and inflammatory responses,
where the genes most sensitive to T. cruzi-mediated inhibition
(EGR1, HBEGF, PTGS2, LIF, EDN1, IL6,a n dCYR61) are known to
be regulated by MAP kinase-activated transcription factors such as
the ETS-family members and AP-1 [43,44,45,46,47,48,49]. In
addition, genes encoding components of the AP-1 complex, c-jun
and c-fos, as well as egr-1 were also rapidly down-regulated in T. cruzi
PCM treated cells, suggesting the disruption of an important
regulatory network centered around MAP kinase signaling, which is
required for efficient expression of ctgf/ccn2 and a host of other
TGF-ß-inducible genes. Consistent with the notion that T. cruzi
might negatively regulate MAP kinase-activated transcription
factors, we demonstrated that a functional Ets-binding site
(spanning 291 and 284 bp) in the upstream ctgf/ccn2 promoter
region, which is critical for TGF-ß stimulated expression of ctgf/ccn2
[15,21,22], is required for T. cruziPCM repressionof both basal and
TGF-ß-stimulated reporter expression. Thus, we propose that the
observed inhibition of agonist-induced phosphorylation of the MAP
kinases, Erk, p38 and JNK, would impact the activation of MAP
kinase-activated transcription factors such as Ets-1. Failure to
assembleEtstranscriptionfactor(s) attheEtsbindingsite,possiblyin
conjunction with other accessory proteins such as AP-1 [21], would
prevent activation of the ctgf/ccn2 promoter in response to signals
mediated by exogenous agonists such as TGF-ß [15]. Overall, our
findings reinforce recent literature regarding the critical role for
MAP kinase signaling in regulation of ctgf/ccn2 expression [9,18,20]
as well as for the role of the Ets-binding site on the ctgf/ccn2
promoter [21,22] in driving ctgf/ccn2 gene expression. Given that
CTGF/CCN2 is a therapeutic target for the prevention and
treatment of a number of disease states in which the expression of
this critical cytokine is dysregulated [10,11,12,13], our finding that
the mammalian-infective forms of T. cruzi release a factor that
interferes with agonist-dependent up-regulation of CTGF/CCN2
warrants further study.
We had shown previously that infection with live T. cruzi
trypomastigotes or parasite-conditioned medium (PCM) causes
rapid dephosphorylation of Erk1/2 and sustained repression of
extracellular matrix protein expression in dermal fibroblasts [7].
Focusing on the secreted/released T. cruzi fraction in this study,
we demonstrate the broad impact of T. cruzi PCM on MAP kinase
signaling where agonist-dependent activation of Erk1/2, p38 and
JNK is thwarted, as is the expression of a subset of TGF-ß-
dependent gene expression. Our findings are consistent with a
Figure 3. The Ets transcription factor binding site in the ctgf/
ccn2 promoter is required for T. cruzi PCM-mediated repression
of reporter expression. SEAP reporter constructs driven by
nucleotides 2805 to +17 (2805), 2244 to +17 (2244), 286 to +17
(286)o r2805 to +17 with a mutated ETS sequence (2805 ETS)
representing the proximal ctgf/ccn2 promoter region (A) along with a ß-
galactosidase containing control plasmid were transfected into HFF. (B)
Serum-starved transfected cells were stimulated with medium alone or
5 ng/ml TGF-ß1 in the presence or absence of T. cruzi PCM for 6 hours.
Relative reporter expression in treated cells relative to mock-treated
controls is shown as the mean 6 s.e. (n=3). (*p,0.05, p,0.01).
doi:10.1371/journal.pone.0023482.g003
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Accession Gene Symbol Gene Description *TGF-ß TGF-ß +
PCM
ECM Remodeling/Angiogenesis
M60278 HBEGF Heparin-binding EGF-like growth factor 50.4 3.7
AF169312 ANGPTL4 Angiopoietin-like 4 42.0 19.9
J05008 EDN1 Endothelin-1 7.3 1.3
BC020765 SERPINE1 PAI-1 6.7 3.9
AI459194 EGR1 Early growth response 1 5.3 0.3
M92934 CTGF Connective tissue growth factor 4.2 2.4
NM_007036 ESM1 Endothelial cell-specific molecule 1 3.4 0.9
AI806905 CHST11 Chondroitin 4 sulfotransferase 11 2.9 1.7
AI524125 PCDH9 Protocadherin 9 2.7 1.6
BC036577 DDAH1 Dimethylarginine dimethylaminohydrolase 1 2.7 1.1
AI694545 PLXNA2 Plexin A2 2.6 1.1
AI860360 TPM1 Tropomyosin 1a 2.5 1.3
AI374739 HAS2 Hyaluronan synthase 2 2.3 1.2
Y13786 ADAM19 ADAM metallopeptidase domain 19 2.2 1.3
AB002373 RUSC2 RUN and SH3 domain containing 2 2.1 1.2
AF003114 CYR61 Cysteine-rich, angiogenic inducer, 61 2.1 0.5
Inflammation/Immunity
NM_000600 IL6 IL-6 4.2 0.8
NM_000963 PTGS2 Prostaglandin-endoperoxide synthase 2 3.1 0.4
S69738 CCL2 Chemokine (C-C motif) ligand 2 2.6 0.9
AI608902 CD274 CD274 antigen 2.5 0.9
U93091 TLR4 Toll-like receptor 4 2.1 0.9
Cell growth/differentiation
BC093735 LIF Leukemia inhibitory factor 6.4 1.0
AK000850 NEDD9 Crk-associated substrate related 6.1 3.4
NM_030751 SNF1LK SNF1-like kinase 3.7 2.1
H94882 ANKRD15 Ankryn repeat domain 15 3.7 1.8
M13436 INHBA Inhibin, beta A 3.3 1.0
AK025317 MAML2 Mastermind-like 2 3.1 1.3
AB011109.1 NUAK1 NUAK family, SNF1-like kinase 3.0 1.4
NM_005118 TNFSF15 Tumor necrosis factor superfamily 15 2.7 1.3
AF329092 DOC1 Anaphase-promoting complex 1 2.4 0.8
AL136919 LRRC8C Leucine rich repeat protein 2.3 1.3
Signaling
AV686810 RHOB RhoB 10.0 4.6
AF087853 GADD45B Growth arrest and DNA-damage-inducible 5.5 2.5
BE302191 STK38L Serine/threonine kinase 38 like 3.3 2.0
AU144916 IGFBP7 Insulin-like growth factor binding protein 7 3.2 1.3
NM_007368 RASA3 RAS p21 protein activator 2.8 1.7
NM_006823 PKIA Protein kinase cAMP-dependent, catalytic) inhbitor 2.7 1.1
AI139993 SH3GLP3 SH3-domain GRB2-like 2.3 0.9
AU157259 SMURF2 SMAD specific E3 ubiquitin protein ligase 2 2.2 1.1
AB043703 FZD8 Frizzled homolog 8 2.2 0.8
NM_004073 PLK3 Cytokine-inducible kinase 2.2 0.8
Transcriptional regulation
NM_000399 EGR2 Early growth response 2 100 60
BG326045 BHLHB2 Basic helix-loop-helix domain containing 6.6 2.7
M60721 HLX1 H2.0-like homeo box 1 4.0 2.1
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cardiomyocytes renders infected cells refractory to TGF-ß-
induced increases in fibronectin expression [52]. While these in
vitro observations provide novel insights into the impact of
infective T. cruzi trypomastigotes on host cell signaling and gene
expression, the ultimate goal would be to measure these events
and outcomes in the context of an in vivo infection. Given the
critical role played by MAP kinases in cell proliferation, wound
healing and host immunity [19,53,54,55]. It is tempting to
speculate that modulation of this signaling pathway early in the T.
cruzi infection process could modulate the local host environment
in favor of the parasite. If, as suggested by in vitro studies, ECM
synthesis and host immune response pathways were to be
repressed at local sites of T. cruzi infection, we would predict
that these events would facilitate the early establishment of
infection in the host. While this would be challenging to test in the
context of ECM homeostasis, the concept of immune evasion
early in the establishment of infection by T. cruzi trypomastigotes
is not new [56]. There are several examples of soluble T. cruzi
immunomodulatory molecules including the trypanosomal im-
munosuppressive factor (TIF) which represses T- and B-cell
functions [57,58,59,60] and a mucin-like protein expressed on the
surface of epimastigotes and metacyclic trypomastigotes (AgC10)
which inhibits LPS-mediated signaling and dendritic cell activa-
tion via MAP kinase [61]. A parasite glycoinositol-phospholipid
[62] and another polypeptide antigen (Ag123) [63] have also been
implicated in modulating the host immune response demon-
strating that T. cruzi may have evolved several overlapping
mechanisms for interfering with normal host immune function.
The T. cruzi molecule(s) responsible for antagonizing TGF-ß
signaling in dermal fibroblasts, that dampen fibrogenic and
immune gene expression, have yet to be identified. Efforts focused
on isolation of this heat-labile, trypsin-sensitive factor have
revealed that it co-fractionates with the major parasite surface
glycoproteins and elutes from an anion exchange column in a
sharp peak with ,200 mM NaCl (A. Mott and B. Burleigh,
Accession Gene Symbol Gene Description *TGF-ß TGF-ß +
PCM
AL120562 KLF7 Kruppel-like factor 7 3.3 1.5
BF436898 ETV6 Ets variant gene 6 (TEL oncogene) 3.1 1.7
NM_005251 FOXC2 MFH-1, mesenchyme forkhead 1 2.9 1.4
NM_012099 CD3EAP CD3-epsilon-associated protein 2.7 1.6
AF247704 NKX3-1 NK3 transcription factor related 2.5 1.3
Other functions
AW138350 ICHTHYIN Ichthyin 33.1 17.8
AW004016 ST6GAL2 Beta-galactosamide a-2,6-sialyltransferase 2 12.6 7.5
AF153330 SLC19A2 Thiamine transporter 5.6 2.6
AK026466 CYFIP2 Cytoplasmic FMR1 interacting protein 2 5.0 2.5
AK026905 MICAL2 Microtubule associated monoxygenase 3.6 1.5
NM_000427 LOR Loricrin 3.2 1.3
AF043472 KCNS3 Potassium voltage-gated channel 2.7 1.4
NM_020127 TUFT1 Tuftelin 2.7 1.6
AI628360 NPR3 Natriuretic peptide receptor C 2.2 1.2
AI091372 AXUD1 TGF-beta-induced apoptosis protein 3 2.2 1.3
Human foreskin fibroblasts were treated with medium or 5 ng/ml TGF- ß1 for 3 hours in the presence and absence of T. cruzi PCM.
TGF-ß1 treatment resulted in a $2-fold up-regulation of 298 unique genes (represented in 309 probe-sets) as compared to cells treated with medium. Genes
highlighted above represent the 59 annotated, non-redundant TGF-ß-inducible genes for which expression is reduced by 1.7-fold or greater in the presence of T. cruzi
PCM in 3 independent experiments. * Values represent the ratio of the normalized log2 intensities for treatment (TGF-ß or TGF-ß/PCM)/mock treated controls.
doi:10.1371/journal.pone.0023482.t001
Table 1. Cont.
Figure 4. T. cruzi PCM inhibits the expression of a broader
range of TGF-ß-inducible genes. Quantitative real-time PCR analysis
of the relative expression of representative PCM-sensitive and PCM-
insensitive TGF-ß-inducible genes in HFF after 2 hours of treatment with
5 ng/mlTGF-ßinmediaorPCM.Genesanalyzed:HBEGF,heparin-binding
EGF-like growth factor; PTSG2, prostaglandin-endoperoxide synthase 2;
CTGF, connective tissue growth factor; Cyr61, cysteine-rich angiogenic
factor; SERPINE2, plasminogen activator inhibitor type 1, member 2;
CDKN2B; cyclin-dependent kinase 4 inhibitor B; SMAD7, MAD, mothers
against decapentaplegic homolog 7; TSPAN2, tetraspanin 2.
doi:10.1371/journal.pone.0023482.g004
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described small shed vesicles [64]. It will be of great interest to
identify the molecular basis for the parasite-dependent repression
to better assess its functional properties and to probe its potential
as a novel antagonist of fibrogenic gene expression and potential
immunosuppressive activity in vitro and in vivo.
Overall, this study highlights the ability of a trypomastigote-
associated soluble factor to dampen basal and agonist-induced
expression of a key regulator of ECM synthesis as well as genes
involved in wound repair and host response to infection. As studies
have clearly demonstrated, T. cruzi infection eventually elicits a
robust inflammatory response in the host where elevated ECM
synthesis and fibrosis are known to contribute to the pathophys-
iology of Chagas’ disease (reviewed in [65]). The cellular responses
to T. cruzi released/secreted factors studied here are immediate/
early in nature and provide insights into potential processes that
would be expected to occur at early time points of infection, where
the parasite-mediated inhibition of host cell fibrogenic gene
expression may serve a critical function in facilitating dissemina-
tion from the initial sites of infection to the circulation and
peripheral organs during acute stages of infection.
Materials and Methods
Cell Culture and Parasite Maintenance
Human foreskin fibroblast (HFF) BJ cells were acquired from
the American Tissue Culture Collection (Manassas, VA, USA) and
maintained in DMEM +10% fetal bovine serum (FBS), 1% pen-
strep, and 2 mM glutamine at 37uCi n5 %C O 2. Tissue culture-
derived Trypanosoma cruzi trypomastigotes (Y strain) were generated
by weekly passage in confluent monolayers of LLcMK2 cells in
DMEM containing 2% FBS as described [5]. Trypomastigotes
harvested from cell culture supernatants were washed 3 times in
cold serum-free DMEM (SF-DMEM), resuspended in warm SF-
DMEM at a concentration of 5610
7 to 1610
8 parasites per ml
and incubated at 37uCi n5 %C O 2 for 14–18 hours. The resulting
‘parasite-conditioned medium’ (PCM) was clarified by centrifuga-
tion of parasites (1000xg) followed by passage through a 0.2 mm
membrane. Prior to treatment of cells, PCM is adjusted to pH 7.4
by addition of a small volume of 1M Tris pH 8.0 and
supplemented with heat-inactivated FBS (95uC, 15 minutes) to
achieve a final concentration of 2%.
Quantitative Real-Time PCR
HFF were seeded in 6-well plates and grown to 80–90%
confluence for 48 hours prior to treatment of cells as indicated.
Following treatment, cells were washed with cold PBS and total
cellularRNAwasharvestedusingtheRNeasyRNAisolationsystem
(Qiagen, Valencia, CA, USA) according to manufacturer’s instruc-
tions. 200 ng of DNaseI-treated RNA (Invitrogen, Carlsbad, CA,
USA) was transcribed to cDNA using the iScript Reverse
Transcription system (BioRad, Hercules, CA, USA). Multiplex
quantitative real-time PCR was carried out using an ABI 7300
instrument. The amount of experimental cDNA was normalized to
GAPDH levels present in the same sample. For quantification of
CTGF/CCN2 mRNA each reaction included 20 nM of each
primer (forward 59-CTGCCCTCGCGGCTTA-39 and reverse
59GGACCAGGCAGTTGGC TCTA-39) and 10 nM FAM-la-
beled CTGF/CCN2 probe (6FAM-ACACGTTTG GCCCA-
GACCCAACTATG-TAMRA). Primers and probes specific for
Figure 5. Top biological network relevant to the subset of PCM-sensitive TGF-ß-inducible genes. Biological network was generated
through the use of Ingenuity Pathway Analysis software (IngenuityH Systems, www.ingenuity.com) by uploading the group of TGF-ß-inducible genes
that were highly sensitive to T. cruzi PCM. The analysis reports direct (solid lines) and indirect (dotted lines) relationships between genes as
established in the literature. Thirteen (shaded symbols) of 15 genes entered into the analysis were included as focus genes in this network.
doi:10.1371/journal.pone.0023482.g005
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and GAPDH gene assays were obtained from Applied Biosystems
Inc. (Foster City, CA, USA).
Western blot Analysis
Relative expression of CTGF/CCN2 was determined in HFF
that were serum-starved for 18 hours prior to treatment with
5 ng/ml TGF-ß for 24 hours in the presence or absence of PCM.
Cells were rinsed in cold PBS, lysed directly in 2X Laemmli Buffer
containing 5% ß-mercaptoethanol (BioRad, Hercules, CA, USA)
and western blot analyses were performed. For MAP kinase
activation, HFF were serum starved for 18 hours prior to
treatment with 10 mM LPA or 5 ng/ml TGF-ß1 with or without
PCM for 5 or 15 minutes. Anti-ß-actin antibodies were purchased
from Sigma (St. Louis, MO, USA); anti-CTGF from Santa Cruz
Biotechnology (Santa Cruz, CA, USA); anti-p44/42, anti-
phospho-p44/p42, anti-p38, anti-phospho-p38, anti-SAPK/JNK
and anti-phospho-SAPK/JNK from Cell Signaling Technology
(Danvers, MA, USA). The ECL Plus chemiluminescence kit
(Amersham Pharmacia, Arlington Heights, IL, USA) was used for
detection. Blots were scanned and band intensity was quantified
using the software program UN-SCAN-IT gel (Silk Scientific
Corporation, Orem, UT, USA).
Transient Transfection and Reporter Assays
HFF were seeded in 6-well plates and grown to 50% confluence
for 24 hours. Cells were transfected with 1 mg of experimental
plasmid DNA and 0.05 mg of control plasmid by lipofection
(FuGENE 6, Roche, Indianapolis, IN, USA) for 3–4 hours in
DMEM +10% FBS. Cells were washed and incubated in DMEM
+10% FBS for an additional 12–14 hours prior to incubation for
6 hours with DMEM-2, PCM prepared in DMEM-2, 5 ng/ml of
TGF-ß1 in the presence and absence of PCM. Promoter/reporter
constructs used contained ctgf/ccn2 promoter fragments spanning
nucleotides 2805 to +17 (2805), 2244 to +17 (2244), 286 to
+17 (286) and a construct identical to 805 with a mutation in the
Ets binding site (2805 ETS) corresponding to a GGAAT to
TCCCG change in the consensus Ets binding motif located in the
transcription enhancing factor (TEF) binding element located
between 291 and 284. All constructs were kindly provided by Dr.
A. Leask [21,27]. Transfection efficiency was measured by co-
transfection with pSV-ß-Galactosidase plasmid. Cells were har-
vested and SEAP and ß-galactosidase assays were performed using
the Luminescent ß-galactosidase Reporter System or Great
EscAPe SEAP Chemiluminescence Kit (Clontech, Mountain
View, CA, USA) according to manufacturer’s instructions.
DNA Microarray Hybridization and Analysis
HFF were mock-treated or stimulated with TGF-ß for 3 hours,
in the presenceor absenceof T. cruzi PCM, rinsed 3 times with PBS.
RNA was isolated with Trizol reagent (Invitrogen, Carlsbad, CA,
USA) and concentrated using an RNeasy kit (Qiagen, Valencia,
CA,USA). RNAintegritywasevaluatedemployinganAgilent2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), three
independent samples for each treatment were processed and
hybridized to individual HG_U133 plus 2.0 Affymetrix chips at
the Harvard Medical School Biopolymers Facility. Arrays were
scanned using a GeneChipH Scanner 3000 (Affymetrix, Santa
Clara, CA, USA) and data files containingthe unprocessed intensity
values were imported into Rosetta Resolver Biosoftware 7.0. Data
were pre-processed to reduce systematic errors (i.e. background
subtraction and intra-array normalization). Through the applica-
tion of the Affymetrix-specific error model within Rosetta Resolver
[66] the data were transformed into profiles (i.e. scanned, imaged
and normalized expression data from a microarray as described in
http://www.rosettabio.com/tech/Data_processing_and_analysis_-
methods.pdf). Intensity ratios were calculated from the statistical
combination of replicate profiles in order to increase the confidence
in measurements and to obtain fold change values and associated
p-values, using the control condition (cells treated with culture
medium) as a baseline. Transcripts showing $2-fold change
(p,0.01) with respect to matched controls were used to create
gene lists and for analysis of biological networks using Ingenuity
Pathway Analysis
TM software (http://www.ingenuity.com). In ac-
cordance to the minimum information about microarray experi-
ment (MIAME) guidelines, the complete raw and processed data
files for each array are publicly available at the Gene Expression
Omnibus (GEO) database repository (http://www.ncbi.nlm.nih.
gov/geo) under accession number GSE16416.
Supporting Information
Table S1 Modulation of fibroblast gene expression by a
secreted/released T. cruzi fraction. Human foreskin
fibroblasts (HFF) were mock-treated or incubated with cell-free
T. cruzi parasite-conditioned medium (PCM) for 3 hours and the
isolated RNA was processed and used to hybridize HG_U133 plus
2.0 Affymetrix arrays. Ratios of the normalized log2 intensities for
PCM vs medium were used to calculate the fold-change in HFF
gene expression for each array and values from 3 biological
replicates were averaged. HFF genes for which the transcript
abundance changes $2-fold in either direction are included.
(XLSX)
Table S2 Inhibition of TGF-ß-inducible gene expression
by T. cruzi PCM. HFF were mock-treated or stimulated with
5 ng/ml TGF-ß1 for 3 hours in the presence or absence of T. cruzi
PCM and cells were processed for microarray hybridization as
described. Ratios of the normalized log2 intensities for TGF-ß vs
medium and TGF-ß+PCM vs medium were used to calculate the
fold-decrease inTGF-ßinduciblegene expression that wasobserved
in the presence of T. cruzi PCM. Only the non-redundant,
annotated genes are shown with the exception of genes for which
duplicates showed marked differences in the fold-change values.
(XLSX)
Table S3 Canonical pathways enriched in the T. cruzi
PCM-sensitive subset of TGF-ß inducible genes. TGF-ß-
inducible genes sensitive to T. cruzi PCM (59 genes from Table 1)
were analyzed using Ingenuity Pathway Analysis software.
Canonical pathways were identified from the Ingenuity Pathways
Analysis library of canonical pathways that were most significant
to the data set and associated with a canonical pathway in
Ingenuity’s Knowledge Base. The significance of the association
between the data set and the canonical pathway was measured in 2
ways: 1) A ratio of the number of molecules from the data set that
map to the pathway divided by the total number of molecules that
map to the canonical pathway is displayed. 2) Fisher’s exact test
was used to calculate a p-value determining the probability that
the association between the genes in the dataset and the canonical
pathway is explained by chance alone.
(XLS)
Table S4 Canonical pathways enriched in the subset of
TGF-ß inducible genes that is insensitive to T. cruzi
PCM. TGF-ß-inducible genes that were insensitive to T. cruzi PCM
(192 genes; Table S2) were analyzed using Ingenuity Pathway
Analysis software and canonical pathways were identified from the
Ingenuity Pathways Analysis library as described for Table S3.
(XLS)
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